Kari M Morrissey
Affiliation: University of California
- Renal transporters in drug developmentKari M Morrissey
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94158, USA
Annu Rev Pharmacol Toxicol 53:503-29. 2013..Renal drug elimination in special populations and transporter splicing variants are also described...
- The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersKari M Morrissey
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA
Clin Pharmacokinet 55:495-506. 2016..This study sought to identify a selective MATE2K inhibitor in vitro and to determine its clinical impact on the pharmacokinetics and pharmacodynamics of metformin in healthy subjects...
- OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metforminLigong Chen
Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, CA 94143 2911 Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China
Proc Natl Acad Sci U S A 111:9983-8. 2014..The studies implicate OCT1 as well as metformin in thiamine disposition, suggesting an intriguing and parallel mechanism for metformin and its major hepatic transporter in metabolic function. ..
- Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modelingMatthias B Wittwer
University of California, San Francisco, Department of Bioengineering and Therapeutic Sciences RH 581, 1550 Fourth Street, San Francisco, California 94158, USA
J Med Chem 56:781-95. 2013..In parallel, a QSAR model identified distinct molecular properties of MATE1 versus OCT2 inhibitors and was used to screen the DrugBank in silico library for new hits in a larger chemical space...